The clinical impact of interferon beta antibodies in relapsing-remitting MS.
about
Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) stuQualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levelsEarly detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.IFNβ secreted by microglia mediates clearance of myelin debris in CNS autoimmunityGuidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.Neutralising antibodies to IFN-beta in patients with multiple sclerosis.Cladribine: an investigational immunomodulatory agent for multiple sclerosis.Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement.Early stage and long term treatment of multiple sclerosis with interferon-betaAntibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients.Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.Determinants of interferon β efficacy in patients with multiple sclerosis.Management of children with multiple sclerosis.Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.In vitro assessment of the biologic activity of interferon beta formulations used for the treatment of relapsing multiple sclerosis.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
P2860
Q31153206-641EC209-B844-4294-9DA7-B748A704B2D3Q33270865-091E0698-ECA8-4AEE-88EB-2AF9E87A6CB5Q33510256-E39918D5-CAD9-4145-97BE-CD60FA3FBFCDQ34207663-AD822C81-7947-4AD3-99E3-0AA40C63B0D0Q34368959-783022A1-A408-455F-824F-688965780DEFQ34491595-65B95692-A5EE-467E-ACBF-0BC422739293Q35247423-09F6D697-26EF-423F-A6A5-29BB851A27BCQ36293497-6EF9A274-9073-4858-B2F4-6E0A0F4B3AE1Q36541952-C4C58C60-E401-44F7-806A-0302DA065C15Q36598122-8C8489D6-8292-4387-8869-092B1E7FAECAQ36840374-B607C352-150A-470E-8031-EE9FA9110D14Q37189729-413EE11B-29EC-4DB1-846B-AF28F8873DEFQ37303237-24B3D6E9-C238-45D1-A5A9-85A1E366A0CCQ37378782-A01AE32D-D3E2-4D11-8F4C-F25CAF00C1EBQ37409559-8BBBC65B-6398-4723-B765-D8640CB6A775Q37562166-761F8B20-3189-4F25-A109-CDEFA21844D8Q37706612-23427C1B-A12D-46C4-9963-F14DD40003FCQ37848651-01354D68-80BC-4C8D-B91B-2396A5103E43Q38002113-B7BC081F-6BE3-4EBB-AB3E-2B2E1184504DQ38174450-AE39F379-280D-4492-874B-9502C0F02CEEQ38657226-4388CCBF-28FB-4CB1-8A26-40BC6FC7D789Q38960854-17FEC751-658B-4DBA-A2A0-0107D1CD68FFQ42595787-F8309ABC-EAF2-4C79-B184-9AD7D3F707B9Q43997002-01A8689F-B127-4641-94B6-9BB1E4F1BD16Q44258171-D005CF13-A374-4FCC-96D1-40E49DCBD93BQ47819826-BD9C9E06-9CC4-4B61-93C1-ACC91637AB2CQ54343194-87017A52-73CA-45AA-A0E2-A57A846BCF03
P2860
The clinical impact of interferon beta antibodies in relapsing-remitting MS.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
The clinical impact of interferon beta antibodies in relapsing-remitting MS.
@en
The clinical impact of interferon beta antibodies in relapsing-remitting MS.
@nl
type
label
The clinical impact of interferon beta antibodies in relapsing-remitting MS.
@en
The clinical impact of interferon beta antibodies in relapsing-remitting MS.
@nl
prefLabel
The clinical impact of interferon beta antibodies in relapsing-remitting MS.
@en
The clinical impact of interferon beta antibodies in relapsing-remitting MS.
@nl
P2093
P1433
P1476
The clinical impact of interferon beta antibodies in relapsing-remitting MS.
@en
P2093
Giovanni Biasi
Massimiliano Calabrese
Paola Perini
Paolo Gallo
P2888
P304
P356
10.1007/S00415-004-0312-8
P577
2004-03-01T00:00:00Z